NCT05432297 Preventive Physical Activity Intervention in Head and Neck Cancer
| NCT ID | NCT05432297 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sahlgrenska University Hospital |
| Condition | Head and Neck Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-01-02 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-01-02 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study includes patients with tumors of the oropharynx, larynx and hypopharynx scheduled to receive radiotherapy with curative intent (+/- chemotherapy). The patients will be randomized into either an intervention group (performing a preventive physical activity protocol before and during radiotherapy) or a control group not performing a specified physical exercise protocol. All patients will be in contact with with a speech language pathologist or a physical therapist weekly during radiotherapy. The study is expected to improve physical function and quality of life during and after oncologic treatment
Eligibility Criteria
Inclusion Criteria: * Head and neck cancer (tumors of the oropharynx, pharynx, hypopharynx and larynx) * Receiving radiohterapy (+/- chemotherapy) with curative intent Exclusion Criteria: * Surgery due to head and neck cancer * Previous treatment for head and neck cancer * Tracheostomized patients * Inability to perform exercise intervention * Inability to perform part of 6-minute walking test * Inability to independently fill out questionnaires in Swedish * Previous neurologic or neuromuscular disease
Contact & Investigator
Lisa Tuomi, PhD
PRINCIPAL INVESTIGATOR
Sahlgrenska University Hospital
Frequently Asked Questions
Who can join the NCT05432297 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05432297 currently recruiting?
Yes, NCT05432297 is actively recruiting participants. Contact the research team at tuomi.lisa@gu.se for enrollment information.
Where is the NCT05432297 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT05432297 clinical trial?
NCT05432297 is sponsored by Sahlgrenska University Hospital. The principal investigator is Lisa Tuomi, PhD at Sahlgrenska University Hospital. The trial plans to enroll 80 participants.